Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Neurol Neurosurg Psychiatry
Hoofdauteurs: van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2019
Onderwerpen:
Neuromuscular
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://ncbi.nlm.nih.gov/pubmed/31292200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2019-320998
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items